Weiguoblood was approved for IPO on the Shanghai Stock Exchange, focusing on the layout of two major tracks: blood dialysis and peritoneal dialysis.

On February 26, Shandong Weigao Blood Purification Products Co., Ltd. (referred to as Weigao Blood Purification) passed the listing committee meeting of the Shanghai Stock Exchange main board IPO. The sponsor institution is Huatai United Securities, intending to raise 1.351 billion yuan. China has a large base of end-stage renal disease (ESRD) patients. According to Frost & Sullivan data, by 2022, the number of ESRD patients in China will reach 3.8547 million, accounting for 36.7% of the global ESRD patient population; and the dialysis treatment rate for domestic ESRD patients still lags behind that of most developed countries/regions. The prospectus shows that in order to better meet the treatment needs of ESRD patients at all stages, Weigao Blood Purification focuses on the two main tracks of blood dialysis and peritoneal dialysis, supplemented by the sales of dialysis ancillary products, making it one of the domestically richest blood purification medical device manufacturers. The company's blood dialysis products mainly include blood dialyzers, blood dialysis tubing, and blood dialysis machines, while peritoneal dialysis products mainly include peritoneal dialysis fluid. Since its establishment, Weigao Blood Purification has always focused on the research and development, production, and sales of blood purification medical products, with the main products of blood dialyzers, blood dialysis tubing, blood dialysis machines, and peritoneal dialysis fluids focusing on the fields of blood dialysis and peritoneal dialysis, supplemented by the sales of dialysis ancillary products, making it one of the domestically richest blood purification medical device manufacturers. After deducting issuance expenses, the actual proceeds from this issuance are intended to be used for the following projects: In terms of finances, in the fiscal years 2021, 2022, 2023, and the first 6 months of 2024, Weigao Blood Purification achieved operating income of approximately 2.911 billion, 3.426 billion, 3.532 billion, and 1.626 billion yuan, respectively. During the same period, the company achieved net profits of approximately 260 million, 315 million, 442 million, and 200 million yuan respectively.